Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Allogeneic Hematopoietic Stem Cell Transplantation For The Treatment Of High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen

NCT00615589 is registered in ClinicalTrials.gov with University of Michigan Rogel Cancer Center as lead sponsor.

NCT NCT00615589
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00615589 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Allogeneic Hematopoietic Stem Cell Transplantation For The Treatment Of High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen
Lead sponsor
University of Michigan Rogel Cancer Center
Phase
Phase 2
Overall status
Terminated
Start date
February 29, 2008
Completion date
January 31, 2013
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, plasma cell leukemia